

ACURA PHARMACEUTICALS, INC
Form 8-K
December 20, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act Of 1934

December 20, 2012

Date of Report (Date of earliest event reported)

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

State of New York	1-10113	11-0853640
(State of Other Jurisdiction (Commission File Number) of Incorporation)		(I.R.S. Employer Identification Number)

616 N. North Court, Suite 120

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

(847) 705-7709

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-J(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))

Item 8.01 Other Events

On December 20, 2012 we issued a press release announcing that we filed an Investigational New Drug application (“IND”) with the U.S. Food and Drug Administration (FDA) to allow clinical testing of Acura’s hydrocodone bitartrate with acetaminophen formulated with Aversion® Technology and that clinical testing can commence under the IND 30-days following the IND filing unless questions are raised by the FDA. A copy of our press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

Exhibit Number Description

99.1 Press Release dated December 20, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA
PHARMACEUTICALS,
INC.

By: /s/ Peter A. Clemens
Peter A. Clemens
Senior Vice President &
Chief Financial Officer

Date: December 20, 2012

Exhibit Index

Exhibit Number Description

99.1 Press Release dated December 20, 2012